Market Summary
USD3.33-0.09
Market Closed-2.63%
TXMD Stock Price
TXMD RSI Chart
TXMD Valuation
TXMD Price/Sales (Trailing)
TXMD Profitability
TXMD Fundamentals
TXMD Revenue
TXMD Earnings
Price Action
52 Week Range
3.307.53
(Low)(High)
Last 7 days
-8.0%
Last 30 days
-11.2%
Last 90 days
-15.5%
Trailing 12 Months
-52.8%
TXMD Financial Health
TXMD Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for TXMD
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-17 | ZIEGLER JOSEPH | acquired | - | - | 7,500 | principal financial officer |
2023-06-28 | Rubric Capital Management LP | acquired | 1,150,000 | 3.6797 | 312,525 | - |
2023-04-26 | Walker Marlan D | sold | -2,517 | 3.6381 | -692 | chief executive officer |
2023-04-26 | Walker Marlan D | acquired | - | - | 2,744 | chief executive officer |
2023-04-12 | Walker Marlan D | sold | -4,275 | 3.6543 | -1,170 | chief executive officer |
2023-04-12 | Walker Marlan D | acquired | - | - | 7,508 | chief executive officer |
2023-04-12 | Donegan Michael C | acquired | - | - | 50,000 | prin. fin. and acctg. officer |
2023-01-27 | Donegan Michael C | sold | -249 | 5.09 | -49.00 | prin. fin. and acctg. officer |
2023-01-26 | Donegan Michael C | acquired | - | - | 5,940 | prin. fin. and acctg. officer |
2023-01-26 | Donegan Michael C | sold | -8,371 | 5.0796 | -1,648 | prin. fin. and acctg. officer |
Which funds bought or sold TXMD recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | added | 584 | 12,634 | 14,571 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | reduced | -12.99 | -69.00 | 1,462 | -% |
2023-08-15 | Clearline Capital LP | added | 8.57 | 303,289 | 1,876,130 | 0.11% |
2023-08-15 | HARBOUR INVESTMENTS, INC. | unchanged | - | 3.00 | 33.00 | -% |
2023-08-14 | Guardian Wealth Management, Inc. | unchanged | - | - | 8.00 | -% |
2023-08-14 | CITADEL ADVISORS LLC | new | - | 499 | 499 | -% |
2023-08-14 | Royal Bank of Canada | added | 73.95 | 2,000 | 5,000 | -% |
2023-08-14 | VANGUARD GROUP INC | unchanged | - | 142,541 | 1,587,220 | -% |
2023-08-14 | STATE STREET CORP | reduced | -0.01 | 11,139 | 124,127 | -% |
2023-08-14 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | 15,540 | 173,040 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of TherapeuticsMD
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jun 30, 2023 | rubric capital management lp | 19.57% | 2,069,716 | SC 13D/A | |
| Aug 30, 2022 | rubric capital management lp | 18.27% | 1,721,953 | SC 13D/A | |
| Jul 08, 2022 | blackrock inc. | 1.4% | 122,138 | SC 13G/A | |
| Jun 03, 2022 | beryl capital management llc | 1.5% | 126,229 | SC 13G | |
| Mar 23, 2022 | smith robert j | 5.38% | 23,103,292 | SC 13D/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 0.1% | 649,807 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 5.9% | 24,894,812 | SC 13G/A | |
| Jul 07, 2021 | flynn james e | 4.90% | 20,662,810 | SC 13G | |
| Feb 16, 2021 | price t rowe associates inc /md/ | 6.2% | 18,869,212 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 4.39% | 13,165,644 | SC 13G/A |
Recent SEC filings of TherapeuticsMD
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 21, 2023 | 4 | Insider Trading | |
| Aug 21, 2023 | 3 | Insider Trading | |
| Aug 18, 2023 | 8-K | Current Report | |
| Aug 14, 2023 | 8-K | Current Report | |
| Aug 14, 2023 | 10-Q | Quarterly Report | |
| Jul 19, 2023 | 4 | Insider Trading | |
| Jul 19, 2023 | 4 | Insider Trading | |
| Jul 19, 2023 | 4 | Insider Trading | |
| Jul 11, 2023 | D | D | |
| Jul 10, 2023 | 8-K | Current Report |
Peers (Alternatives to TherapeuticsMD)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 517.3B | 29.5B | 5.22% | 88.98% | 79.61 | 17.53 | 1.53% | 14.16% |
JNJ | 421.5B | 97.8B | -5.97% | -1.12% | 32.29 | 4.31 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -1.68% | 25.60% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 191.9B | 77.9B | -7.28% | -24.56% | 8.94 | 2.46 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.53% | -15.83% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.68% | 536.50% | -74 | 4.1K | -86.94% | 71.24% |
PRGO | 4.5B | 4.6B | -12.08% | -16.86% | -67.03 | 0.98 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.9B | 627.1M | -7.75% | -1.79% | -1.34 | 3.1 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -8.17% | -19.68% | 35.6 | 2.43 | 0.62% | -24.59% |
CRON | 842.2M | 109.5M | 18.82% | -27.78% | -5.87 | 7.69 | -2.66% | -32.13% |
INVA | 814.0M | 244.3M | -8.50% | 0.08% | 4.13 | 3.33 | -39.50% | -4.99% |
CGC | 567.0M | 453.3M | 123.19% | -68.11% | -0.46 | 1.25 | -16.04% | 55.90% |
PAHC | 505.9M | 977.9M | -17.56% | -11.73% | 15.52 | 0.52 | 3.78% | -33.69% |
OPNT | 106.7M | - | 2.08% | -28.79% | -3.22 | 2.72 | - | - |
TXMD | 35.2M | - | -11.20% | -52.83% | 0.82 | 0.55 | -19.54% | 257.52% |
TherapeuticsMD News
Returns for TXMD
Cumulative Returns on TXMD
-31.0%
10-Year Cumulative Returns
-48.1%
7-Year Cumulative Returns
-60.3%
5-Year Cumulative Returns
-64.2%
3-Year Cumulative Returns
Risks for TXMD
What is the probability of a big loss on TXMD?
100%
Probability that TherapeuticsMD stock will be more than 20% underwater in next one year
99.6%
Probability that TherapeuticsMD stock will be more than 30% underwater in next one year.
96.9%
Probability that TherapeuticsMD stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does TXMD drawdown profile look like?
Y-axis is the maximum loss one would have experienced if TherapeuticsMD was unfortunately bought at previous high price.
Drawdowns
Financials for TherapeuticsMD
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | - | - | - | 69,963,000 | 69,235,333 | 68,507,667 | 67,780,000 | 86,951,000 | 90,851,000 | 84,787,000 | 72,487,000 | 64,872,000 | 58,196,000 | 62,573,000 | 57,951,000 | 49,647,000 | 38,834,000 | 18,588,535 | 16,272,545 | 16,098,937 | 15,134,937 | 16,079,402 |
| Gross Profit | 1.4% | 31,125,000 | 30,688,000 | 68,566,000 | 45,543,000 | 48,538,000 | 67,407,000 | 68,113,000 | 71,169,000 | 67,108,000 | 54,540,000 | 48,897,000 | 44,923,000 | 51,135,000 | 49,664,000 | 43,312,000 | 34,428,000 | 14,928,000 | 13,407,000 | 13,362,000 | 12,753,000 | 13,695,000 |
| Operating Expenses | -612.4% | -9,997,000 | 1,951,000 | 67,375,000 | -7,194,000 | 14,975,000 | 54,166,000 | 80,748,000 | 210,154,000 | 191,146,000 | 188,437,000 | 204,438,000 | 210,248,537 | 218,558,220 | 213,686,098 | 194,517,000 | 179,361,869 | 167,150,850 | 157,014,725 | 143,581,978 | 126,532,660 | 107,945,721 |
| S&GA Expenses | -35.8% | 21,166,000 | 32,960,000 | 57,903,000 | 45,805,000 | 56,681,000 | 74,270,000 | 80,748,000 | 112,189,000 | 104,557,000 | 102,280,000 | 117,052,000 | 102,301,481 | 125,055,467 | 136,555,918 | 114,231,000 | 156,789,394 | 142,016,480 | 130,095,799 | 115,988,954 | 94,757,037 | 76,460,833 |
| R&D Expenses | - | - | - | - | 5,512,000 | 6,005,000 | 6,436,000 | 7,086,000 | 8,060,000 | 8,482,000 | 9,213,000 | 10,432,000 | 12,470,012 | 14,520,750 | 16,743,118 | 19,792,000 | 22,113,178 | 24,743,711 | 26,577,723 | 27,299,138 | 31,520,904 | 31,249,435 |
| EBITDA | -100.0% | - | 47,859,000 | 15,812,000 | 34,325,000 | 18,810,000 | -142,449,000 | -135,405,000 | -139,166,967 | -124,138,180 | -133,974,925 | -153,900,924 | -163,212,450 | -164,765,792 | -171,165,387 | -158,149,998 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.68 | 0.23 | 0.39 | 0.20 | -1.65 | -1.56 | -1.53 | -1.46 | -1.85 | -2.37 | -2.80 | -2.63 | -2.95 | -3.19 | - | - | - | - | - | - |
| Interest Expenses | 0.4% | -12,427,000 | -12,472,000 | 13,545,000 | 9,924,000 | 12,609,000 | 20,205,000 | 25,068,000 | 32,953,000 | 33,115,000 | 32,546,000 | 28,581,000 | 26,633,368 | 24,552,373 | 21,553,982 | 17,382,000 | 13,811,007 | 10,265,079 | 6,767,852 | 4,677,834 | 5,168,918 | 2,125,528 |
| Earnings Before Taxes | 15.6% | -67,460,000 | -79,919,000 | 1,074,000 | -11,823,000 | -30,018,000 | -57,797,000 | -79,305,000 | -171,542,000 | -156,734,000 | -166,058,000 | -183,524,000 | -190,872,515 | -190,227,108 | -193,487,625 | -176,145,000 | -166,100,466 | -169,739,175 | -147,721,706 | -132,617,160 | -114,653,509 | -93,712,848 |
| EBT Margin | -100.0% | - | 0.68 | 0.02 | -0.10 | -0.29 | -2.11 | -1.98 | -1.89 | -1.85 | -2.29 | -2.83 | -3.28 | -3.04 | -3.34 | -3.55 | - | - | - | - | - | - |
| Net Income | -72.9% | 42,720,000 | 157,415,000 | 111,997,000 | -8,665,000 | -27,120,000 | -182,053,000 | -172,415,000 | -171,542,000 | -156,734,000 | -166,058,000 | -183,524,000 | -190,872,000 | -190,227,000 | -193,488,000 | -176,145,000 | -166,101,000 | -169,739,000 | -147,721,000 | -132,617,000 | -114,653,000 | -93,713,000 |
| Net Income Margin | -100.0% | - | 2.25 | 1.60 | -0.10 | -0.29 | -2.11 | -1.98 | -1.89 | -1.85 | -2.29 | -2.83 | -3.28 | -3.04 | -3.34 | -3.55 | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 18,530,000 | 9,359,000 | -103,429,000 | -122,661,000 | -133,852,000 | -142,727,000 | -133,658,959 | -129,603,000 | -158,988,174 | -159,677,408 | -180,311,148 | -173,468,453 | -168,854,278 | -168,147,880 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -9.9% | 54.00 | 60.00 | 90.00 | 134 | 146 | 133 | 169 | 210 | 211 | 239 | 182 | 177 | 206 | 269 | 266 | 250 | 247 | 182 | 212 | 237 | 172 |
| Current Assets | -20.7% | 20.00 | 25.00 | 55.00 | 87.00 | 99.00 | 84.00 | 119 | 160 | 160 | 187 | 128 | 122 | 149 | 212 | 208 | 192 | 216 | 153 | 187 | 212 | 167 |
| Cash Equivalents | 0% | 49.00 | 49.00 | 38.00 | 38.00 | 65.00 | 65.00 | 79.00 | 105 | 111 | 138 | 80.00 | 80.00 | 114 | 170 | 161 | 155 | 183 | 123 | 162 | 190 | 154 |
| Inventory | - | - | - | - | 7.00 | 6.00 | 9.00 | 8.00 | 7.00 | 8.00 | 7.00 | 8.00 | 10.00 | 10.00 | 15.00 | 12.00 | 11.00 | 7.00 | 5.00 | 3.00 | 2.00 | 2.00 |
| Net PPE | -32.8% | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Liabilities | -18.4% | 22.00 | 28.00 | 55.00 | 182 | 172 | 274 | 263 | 267 | 260 | 249 | 306 | 293 | 300 | 314 | 257 | 271 | 238 | 121 | 114 | 103 | 94.00 |
| Current Liabilities | -25.7% | 14.00 | 19.00 | 47.00 | 174 | 164 | 265 | 253 | 86.00 | 76.00 | 61.00 | 59.00 | 47.00 | 46.00 | 62.00 | 53.00 | 67.00 | 42.00 | 45.00 | 41.00 | 29.00 | 21.00 |
| LT Debt, Current | - | - | - | - | 94.00 | 91.00 | 203 | 188 | 15.00 | 10.00 | 5.00 | - | - | - | - | - | - | - | - | - | - | - |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | 172 | 175 | 179 | 238 | 237 | 244 | 243 | 195 | 194 | 194 | 74.00 | 73.00 | 73.00 | 73.00 |
| Shareholder's Equity | -2.6% | 31.00 | 32.00 | 35.00 | - | -26.07 | -140 | -93.62 | - | - | - | - | - | - | - | 9.00 | - | 8.00 | 61.00 | 98.00 | 134 | 78.00 |
| Retained Earnings | -0.3% | -945 | -942 | -939 | -1,017 | -988 | -1,100 | -1,051 | -1,008 | -960 | -918 | -878 | -836 | -804 | -752 | -695 | -645 | -614 | -558 | -519 | -479 | -444 |
| Additional Paid-In Capital | 0.2% | 977 | 975 | 974 | 969 | 962 | 960 | 958 | 951 | 912 | 908 | 755 | 721 | 710 | 707 | 704 | 625 | 622 | 619 | 617 | 614 | 522 |
| Shares Outstanding | 10.8% | 11.00 | 10.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 93.5% | 35,859 | 18,530 | 9,359 | -15,848 | -28,814 | -34,625 | -55,133 | -133,492 | -129,318 | -158,740 | -159,471 | -179,931 | -172,105 | -166,665 | -165,718 | -143,045 | -150,890 | -125,325 | -106,811 | -99,472 | -82,088 |
| Share Based Compensation | -18.0% | 8,198 | 9,994 | 11,572 | 13,933 | 16,953 | 17,229 | 18,125 | 14,956 | 10,777 | 11,270 | 10,679 | 11,325 | 10,827 | 10,461 | 10,682 | 10,133 | 9,758 | 9,498 | 8,662 | 8,240 | 7,966 |
| Cashflow From Investing | - | - | - | -355 | 140,802 | -1,984 | -1,997 | -2,223 | -1,203 | -1,283 | -1,593 | -1,598 | -21,817 | -22,857 | -23,669 | -23,892 | -3,849 | -22,882 | -21,983 | -21,497 | -21,178 | -915 |
| Cashflow From Financing | -Infinity% | -220,412 | - | -235,206 | -103,905 | -91,825 | 28,603 | 129,552 | 159,902 | 128,186 | 127,852 | 80,725 | 126,053 | 125,956 | 237,549 | 188,827 | 112,226 | 202,232 | 162,843 | 162,787 | 162,357 | 140,915 |
TXMD Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Total revenue, net | $ 437 | $ 348 | $ 853 | $ 1,043 |
| Cost of revenue | 348 | 1,043 | ||
| Gross profit | 437 | 0 | 853 | 0 |
| Operating expenses: | ||||
| Selling, general and administrative | 2,781 | 14,575 | 5,837 | 32,121 |
| Depreciation & amortization | 128 | 282 | 155 | 611 |
| Total operating expenses | 2,909 | 14,857 | 5,992 | 32,732 |
| Loss from operations | (2,472) | (14,857) | (5,139) | (32,732) |
| Other (expense) income: | ||||
| Interest expense and other financing costs | (45) | 0 | (95) | 0 |
| Miscellaneous income (expense) | 103 | (16) | 510 | (16) |
| Total other income (loss), net | 58 | (16) | 415 | (16) |
| Income (loss) from continuing operations before income taxes | (2,414) | (14,873) | (4,724) | (32,748) |
| Income (loss) from discontinued operations, net of income taxes | 0 | 127,154 | (1,293) | 96,008 |
| Net income (loss) | $ (2,414) | $ 112,281 | $ (6,017) | $ 63,260 |
| Income (loss) per common share, basic: | ||||
| Continuing operations | $ (0.24) | $ (1.7) | $ (0.47) | $ (3.77) |
| Discontinued operations, net | 0 | 14.53 | (0.13) | 11.06 |
| Net income (loss) per common share, basic | (0.24) | 12.83 | (0.6) | 7.29 |
| Income (loss) per common share, diluted: | ||||
| Continuing operations | (0.24) | (1.7) | (0.47) | (3.77) |
| Discontinued operations, net | 0 | 14.53 | (0.13) | 11.06 |
| Net income (loss) per common share, diluted | $ (0.24) | $ 12.83 | $ (0.6) | $ 7.29 |
| Weighted average common shares, basic | 10,219 | 8,750 | 9,988 | 8,682 |
| Weighted average common shares, diluted | 10,219 | 8,750 | 9,988 | 8,682 |
| Comprehensive income (loss): | ||||
| Net income (loss) | $ (2,414) | $ 112,281 | $ (6,017) | $ 63,260 |
| Other comprehensive income | ||||
| Comprehensive income (loss): | $ (2,414) | $ 112,281 | $ (6,017) | $ 63,260 |
TXMD Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash | $ 13,729 | $ 38,067 |
| Restricted cash | 11,250 | |
| Royalty receivable, current portion | 841 | |
| Prepaid and other current assets | 5,043 | 6,034 |
| Total current assets | 19,613 | 55,351 |
| Fixed assets, net | 39 | 78 |
| License rights and other intangible assets, net | 6,767 | 6,943 |
| Right of use assets | 7,228 | 7,580 |
| Royalty receivable, long term | 19,788 | 20,253 |
| Other non-current assets | 254 | 253 |
| Total assets | 53,689 | 90,458 |
| Current liabilities: | ||
| Accounts payable | 1,508 | 2,162 |
| Accrued expenses and other current liabilities | 11,484 | 18,846 |
| Current liabilities of discontinued operations | 1,372 | 25,831 |
| Total current liabilities | 14,364 | 46,839 |
| Operating lease liabilities | 6,939 | 7,369 |
| Other non-current liabilities | 1,189 | 1,107 |
| Total liabilities | 22,492 | 55,315 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity (deficit): | ||
| Common stock, par value $0.001; 32,000 and 12,000 shares authorized, 10,575 and 9,498 issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 11 | 9 |
| Additional paid-in capital | 976,566 | 974,497 |
| Accumulated deficit | (945,380) | (939,363) |
| Total stockholders' equity | 31,197 | 35,143 |
| Total liabilities and stockholders' equity | $ 53,689 | $ 90,458 |
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.